88 related articles for article (PubMed ID: 32999190)
21. IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia.
Zhang CP; Tian Y; Zhang M; Tuo QH; Chen JX; Liao DF
Med Hypotheses; 2016 Jan; 86():138-42. PubMed ID: 26601593
[TBL] [Abstract][Full Text] [Related]
22. The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins.
Fischer AW; Albers K; Krott LM; Hoffzimmer B; Heine M; Schmale H; Scheja L; Gordts PLSM; Heeren J
Mol Metab; 2018 Oct; 16():88-99. PubMed ID: 30100244
[TBL] [Abstract][Full Text] [Related]
23. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
24. Low-density lipoprotein receptor is a calcium/magnesium sensor - role of LR4 and LR5 ion interaction kinetics in low-density lipoprotein release in the endosome.
Martínez-Oliván J; Rozado-Aguirre Z; Arias-Moreno X; Angarica VE; Velázquez-Campoy A; Sancho J
FEBS J; 2014 Jun; 281(11):2638-58. PubMed ID: 24720672
[TBL] [Abstract][Full Text] [Related]
25. Modifications in low-density lipoprotein receptor expression affects Cyclosporin A cellular uptake and cytotoxicity.
Leon C; Jia J; Qiu G; Hill JS; Wasan KM
J Pharm Sci; 2008 Jun; 97(6):2350-61. PubMed ID: 17823952
[TBL] [Abstract][Full Text] [Related]
26. The important role for betaVLDLs binding at the fourth cysteine of first ligand-binding domain in the low-density lipoprotein receptor.
Iwasaki T; Takahashi S; Ishihara M; Takahashi M; Ikeda U; Shimada K; Fujino T; Yamamoto TT; Hattori H; Emi M
J Hum Genet; 2004; 49(11):622-628. PubMed ID: 15459764
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels.
Goedeke L; Rotllan N; Canfrán-Duque A; Aranda JF; Ramírez CM; Araldi E; Lin CS; Anderson NN; Wagschal A; de Cabo R; Horton JD; Lasunción MA; Näär AM; Suárez Y; Fernández-Hernando C
Nat Med; 2015 Nov; 21(11):1280-9. PubMed ID: 26437365
[TBL] [Abstract][Full Text] [Related]
28. The association between insulin and low-density lipoprotein receptors.
Ramakrishnan G; Arjuman A; Suneja S; Das C; Chandra NC
Diab Vasc Dis Res; 2012 Jul; 9(3):196-204. PubMed ID: 22278734
[TBL] [Abstract][Full Text] [Related]
29. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
30. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development.
Hiltunen TP; Luoma JS; Nikkari T; Ylä-Herttuala S
Circulation; 1998 Mar; 97(11):1079-86. PubMed ID: 9531255
[TBL] [Abstract][Full Text] [Related]
31. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2.
Chen Y; Hughes-Fulford M
Int J Cancer; 2001 Jan; 91(1):41-5. PubMed ID: 11149418
[TBL] [Abstract][Full Text] [Related]
32. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
[TBL] [Abstract][Full Text] [Related]
33. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
Véniant MM; Zlot CH; Walzem RL; Pierotti V; Driscoll R; Dichek D; Herz J; Young SG
J Clin Invest; 1998 Oct; 102(8):1559-68. PubMed ID: 9788969
[TBL] [Abstract][Full Text] [Related]
34. A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.
Holla ØL; Strøm TB; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Feb; 99(2):149-56. PubMed ID: 19828345
[TBL] [Abstract][Full Text] [Related]
35. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis.
Masana L; Girona J; Ibarretxe D; Rodríguez-Calvo R; Rosales R; Vallvé JC; Rodríguez-Borjabad C; Guardiola M; Rodríguez M; Guaita-Esteruelas S; Oliva I; Martínez-Micaelo N; Heras M; Ferré R; Ribalta J; Plana N
J Clin Lipidol; 2018; 12(2):292-299.e3. PubMed ID: 29398429
[TBL] [Abstract][Full Text] [Related]
37. Cholesterol in LDL receptor recycling and degradation.
Yang HX; Zhang M; Long SY; Tuo QH; Tian Y; Chen JX; Zhang CP; Liao DF
Clin Chim Acta; 2020 Jan; 500():81-86. PubMed ID: 31770510
[TBL] [Abstract][Full Text] [Related]
38. APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
Fu T; Guan Y; Xu J; Wang Y
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):883-889. PubMed ID: 28495363
[TBL] [Abstract][Full Text] [Related]
39. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
[TBL] [Abstract][Full Text] [Related]
40. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts.
Datta G; Chaddha M; Garber DW; Chung BH; Tytler EM; Dashti N; Bradley WA; Gianturco SH; Anantharamaiah GM
Biochemistry; 2000 Jan; 39(1):213-20. PubMed ID: 10625496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
